Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gross Profit (2016)

Viridian Therapeutics, Inc.\DE has reported Gross Profit over the past 3 years, most recently at $696000.0 for Q4 2016.

  • For Q4 2016, Gross Profit rose 825.0% year-over-year to $696000.0; the TTM value through Dec 2016 reached $1.9 million, up 51.97%, while the annual FY2016 figure was -$1.0 million, 4690.48% down from the prior year.
  • Gross Profit for Q4 2016 was $696000.0 at Viridian Therapeutics, Inc.\DE, up from $337000.0 in the prior quarter.
  • Over five years, Gross Profit peaked at $1.7 million in Q3 2014 and troughed at -$1.6 million in Q4 2014.
  • A 3-year average of $441750.0 and a median of $522000.0 in 2015 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: tumbled 104.46% in 2015 and later soared 825.0% in 2016.
  • Year by year, Gross Profit stood at -$1.6 million in 2014, then soared by 93.84% to -$96000.0 in 2015, then soared by 825.0% to $696000.0 in 2016.
  • Business Quant data shows Gross Profit for VRDN at $696000.0 in Q4 2016, $337000.0 in Q3 2016, and $487000.0 in Q2 2016.